Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Date
2021
Author
Gullo, Giuseppe
Gao, Bo
Li, Siyu
Lee, Sue
McGuire, Kristina
Chen, Chieh-
Makharadze, Tamta
PAYDAŞ, SEMRA
Nechaeva, Marina
Seebach, Frank
Weinreich, David M.
Yancopoulos, George D.
Lowy, Israel
Rietschel, Petra
Sezer, Ahmet
KILIÇKAP, SAADETTİN
GÜMÜŞ, MAHMUT
Bondarenko, Igor
ÖZGÜROĞLU, Mustafa
Gogishvili, Miranda
TÜRK, HACI MEHMET
ÇİÇİN, İRFAN
Bentsion, Dmitry
Gladkov, Oleg
Clingan, Philip
Sriuranpong, Virote
Rizvi, Naiyer
Metadata
Show full item record
Abstract
Background We aimed to examine cemiplimab, a programmed cell death 1 inhibitor, in the first-line treatment of advanced non-small-cell lung cancer with programmed cell death ligand 1 (PD-L1) of at least 50%.
URI
http://hdl.handle.net/20.500.12627/171314
https://doi.org/10.1016/s0140-6736(21)00228-2
Collections